Ortho-Clinical and Caprion in deal on vCJD (variant-Creutzfeldt- Jakob disease) blood test
This article was originally published in Clinica
Executive Summary
An agreement to develop what might become the world's first human blood test for variant CJD has been struck between Johnson & Johnson subsidiary Ortho-Clinical Diagnostics (OCD) and Canadian company Caprion Pharmaceuticals. The deal, an extension of an R&D collaboration between the two, will give Raritan, New Jersey-based OCD exclusive worldwide marketing and distribution rights to the product for human IVD applications.